Skip to main content
Emergent BioSolutions closes PaxVax deal
10/5/2018

Emergent BioSolutions has purchased PaxVax for $270 million. PaxVax produces two specialty vaccines: Vivotif, the only oral vaccine approved for prevention of typhoid fever, and Vaxchora, the only FDA-approved vaccine for preventing cholera.

Full Story: